Search

V1003

V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. … Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both

Olokizumab

[A241185, A241175] Olokizumab is a humanized anti-IL-6 IgG4κ antibody that directly blocks gp130 binding at IL-6 Site 3.[A241045] … Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system.

MIV-701

MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

LY-517717

LY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).

Butylated hydroxytoluene

Glycocyamine

Drostanolone propionate

NAV 1800

RIGScan CR49, a 125I-labelled CR monoclonal antibody directed against the tumour-associated antigen TAG-72, is undergoing development with Neoprobe for the intraoperative detection of metastatic colorectal

AME-527

AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. … AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

Evofosfamide

TH-302 is a nitroimidazole-linked prodrug of a brominated derivative of an isophosphoramide mustard previously used in cancer drugs such as ifosfamide, cyclophosphamide, and glufosfamide. … TH-302 has been shown, in preclinical studies, to be both efficacious and well tolerated.